Showing 5401-5410 of 8224 results for "".
- Restylane Lyft Approved for Cheek Augmentation and Midface Contour Deficiencieshttps://practicaldermatology.com/news/restylane-lyft-approved-for-cheek-augmentation-and-midface-contour-deficiencies/2458917/The FDA approved Galderma's Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane Lyft, formerly marketed as Perlane-L, is an injectable gel used to increase volume and smooth wrinkles in the face. With t
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- David Dobrowski Named Vice President, Head of North American Research and Development at Merzhttps://practicaldermatology.com/news/david-dobrowski-named-vice-president-head-of-north-american-research-and-development-at-merz/2458921/Merz North American appointed David Dobrowski Vice President and Head of North American Research and Development, effective immediately. In this role, Mr. Dobrowski is responsible for all medical, regulatory, and product safety functions for Merz in North America. He leads the planning and execut
- National Psoriasis Foundation Awards Half a Million Dollars in Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-half-a-million-dollars-in-fellowships/2458922/Eleven early-career physicians each received a one-year, $50,000 National Psoriasis Foundation Medical Dermatology Fellowship to study psoriasis and psoriatic arthritis. These fellowships will help increase the number of scientists studying
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine Ahttps://practicaldermatology.com/news/immune-pharmaceuticals-expands-immuno-dermatology-development-portfolio-with-topical-nano-formulated-cyclosporine-a/2458932/Immune Pharmaceuticals Inc. entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclospo
- ASDSA Supports FDA Fillers Directivehttps://practicaldermatology.com/news/asdsa-supports-fda-fillers-directive/2458935/A recent FDA directive that soft-tissue filler manufacturers include additional precautions on product labels underscores the importance of patients seeking expert physicians for their treatments, according to the American Society for Dermatologic Surgery Association (ASDSA). The FDA is a
- arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditionshttps://practicaldermatology.com/news/argen-x-and-leo-pharma-enter-into-alliance-to-develop-antibody-based-treatments-for-skin-conditions/2458940/arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma entered into an alliance in which they will collaborate to develop antibody-based solutions for the treatment
- The American Academy of Dermatology Elects New Officers and Board Membershttps://practicaldermatology.com/news/the-american-academy-of-dermatology-elects-new-officers-and-board-members/2458941/The American Academy of Dermatology (AAD) announced the results of its annual election. The newly elected officers and board members will lead the AAD, which represents more than 19,000 physicians. These officers and board members also will hold the same positions for the American Academy of Derm